Janet Mj Hammond - 31 Jan 2026 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Reporting relationship: Chief Development Officer
Issuer ticker: AVIR
Reported as of: 31 Jan 2026
Net transaction value: -$59,937
SEC form: 4
Accepted by SEC: 03 Feb 2026, 19:46:49 UTC
Prior SEC filing: 04 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrea Corcoran, as Attorney-in-Fact for Janet Hammond

Key filing fact

Janet Mj Hammond filed Form 4 for Atea Pharmaceuticals, Inc. (AVIR) on 03 Feb 2026.

Key facts

This page summarizes Janet Mj Hammond's Form 4 filing for Atea Pharmaceuticals, Inc. (AVIR).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 03 Feb 2026, 19:46.

Change

Previous filing in this sequence was filed on 04 Feb 2025.
Current net transaction value: -$59,937.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001829899 Primary reporting owner

Hammond Janet MJ

Relationship: Chief Development Officer
Address: 225 FRANKLIN STREET, SUITE 2100, BOSTON
Signature: /s/ Andrea Corcoran, as Attorney-in-Fact for Janet Hammond
Signature date: 03 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVIR transaction

Common Stock

Options Exercise

Transaction value
Shares: +58,050
Change %: +69%
Price
Shares after: 141,801
Date: 31 Jan 2026
Ownership: Direct
Footnotes: F1, F2

AVIR transaction

Common Stock

Tax liability

Transaction value: $59,937
Shares: -14,136
Change %: -10%
Price: $4.24
Shares after: 127,665
Date: 31 Jan 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVIR transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -46,800
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 31 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 46,800
Exercise price
Footnotes: F1, F3

AVIR transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -11,250
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 31 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,250
Exercise price
Footnotes: F1, F4

AVIR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +177,000
Change %
Price: $0.000000
Shares after: 177,000
Date: 31 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 177,000
Exercise price: $4.24
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

Includes 2,363 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.

Footnote F3

The original grant of 140,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

Footnote F4

Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

Footnote F5

The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.